ReviewAdvanced pharmaceutical bulletin2016
Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.
Review in Advanced pharmaceutical bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 96 citations in OpenAlex.
- Recent advances in potential drug nanocarriers for CNS disorders: a review.Biomedical engineering online · 2025Review
- Neuromorphic chips for biomedical engineering.Mechanobiology in medicine · 2025Review
- Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery.RSC advances · 2025Review
- Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.Current pharmaceutical design · 2025Review
- Numerical simulation study of nanoparticle diffusion in gray matter.Computational and structural biotechnology journal · 2024Article
- Nanomedicine in Neuroprotection, Neuroregeneration, and Blood-Brain Barrier Modulation: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024Review
- Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications.3 Biotech · 2024Review
- Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders.Current drug targets · 2024Review
- Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review.ADMET & DMPK · 2024Review
- How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.International journal of nanomedicine · 2024Review
- Quercetin nanoparticles as a therapeutic approach: pharmacological actions and potential applications in therapy.Biotechnologia · 2024Review
- Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches.Cureus · 2023Review
- Caffeic acid recarbonization: A green chemistry, sustainable carbon nano material platform to intervene in neurodegeneration induced by emerging contaminants.Environmental research · 2023Article
- Quercetin and Its Nano-Formulations for Brain Tumor Therapy-Current Developments and Future Perspectives for Paediatric Studies.Pharmaceutics · 2023Review
- Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment.Pharmaceutics · 2023Review
- Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration.Nanomaterials (Basel, Switzerland) · 2022Review
- Emerging scaffold- and cellular-based strategies for brain tissue regeneration and imaging.In vitro models · 2022Review
- The Contribution of Gut Microbiota and Endothelial Dysfunction in the Development of Arterial Hypertension in Animal Models and in Humans.International journal of molecular sciences · 2022Review
- Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance.Frontiers in cell and developmental biology · 2022Review
- MicroRNA-21 Is a Versatile Regulator and Potential Treatment Target in Central Nervous System Disorders.Frontiers in molecular neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.